UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

The New England journal of medicine, 2021-03, Vol.384 (9), p.795-807

2021

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Journal of clinical oncology, 2019-05, Vol.37 (15), p.1277-1284

2019

Link zum Volltext

Verfügbarkeit prüfen

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Blood, 2020-03, Vol.135 (11), p.791-803

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Blood, 2017-11, Vol.130 (22), p.2401-2409

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-08, Vol.156 (8), p.863

2020

Link zum Volltext

Verfügbarkeit prüfen

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

The New England journal of medicine, 2015-01, Vol.372 (1), p.30-39

2015

Link zum Volltext

Verfügbarkeit prüfen

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Blood, 2017-11, Vol.130 (22), p.2392-2400

2017

Link zum Volltext

Verfügbarkeit prüfen

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

Pharmacotherapy, 2020-05, Vol.40 (5), p.416-437

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Journal of clinical oncology, 2017-03, Vol.35 (8), p.826-833

2017

Link zum Volltext

Verfügbarkeit prüfen

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

The New England journal of medicine, 2018-01, Vol.378 (4), p.354-369

2018

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

The New England journal of medicine, 2019-06, Vol.380 (23), p.2225-2236

2019

Link zum Volltext

Verfügbarkeit prüfen

Two Phase 3 Trials of Baricitinib for Alopecia Areata

The New England journal of medicine, 2022-05, Vol.386 (18), p.1687-1699

2022

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

The New England journal of medicine, 2021-10, Vol.385 (17), p.1547-1558

2021

Link zum Volltext

Verfügbarkeit prüfen

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Journal of clinical oncology, 2019-06, Vol.37 (17), p.1460-1469

2019

Link zum Volltext

Verfügbarkeit prüfen

JAK inhibitors in dermatology: The promise of a new drug class

Journal of the American Academy of Dermatology, 2017-04, Vol.76 (4), p.736-744

2017

Link zum Volltext

Verfügbarkeit prüfen

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

The New England journal of medicine, 2020-08, Vol.383 (7), p.617-629

2020

Link zum Volltext

Verfügbarkeit prüfen

Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.719-730

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Cancer discovery, 2016-10, Vol.6 (10), p.1106-1117

2016

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

The New England journal of medicine, 2018-03, Vol.378 (12), p.1107-1120

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2016-01, Vol.374 (4), p.311-322

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2020-07, Vol.396 (10246), p.255-266

2020

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib and Venetoclax for First-Line Treatment of CLL

The New England journal of medicine, 2019-05, Vol.380 (22), p.2095-2103

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-12, Vol.156 (12), p.1333

2020

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

The New England journal of medicine, 2017-06, Vol.376 (22), p.2134-2146

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 7.199

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.065)
Mit Volltextzugriff
(4.728)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(6.584)
Sulfonamides - Adverse Effects
(5.277)
Science & Technology
(5.187)
Life Sciences & Biomedicine
(5.096)
Male
(3.714)
Female
(3.356)
Sulfonamides - Therapeutic Use
(2.831)
Middle Aged
(2.712)
Aged
(2.185)
Adult
(2.179)
Sulfonamides - Administration & Dosage
(1.825)
Biological And Medical Sciences
(1.463)
Medical Sciences
(1.448)
Treatment Outcome
(1.284)
Pharmacology & Pharmacy
(1.246)
Celecoxib
(1.065)
Pharmacology. Drug Treatments
(924)
Animals
(912)
Sulfonamides - Pharmacology
(855)
Anti-Inflammatory Agents, Non-Steroidal - Adverse Effects
(791)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The New England Journal Of Medicine
(105)
The Lancet
(76)
Clinical Therapeutics
(68)
Journal Of Clinical Oncology
(66)
Bmj
(65)
Drugs
(57)
Clinical Cancer Research
(56)
Journal Of Clinical Pharmacology
(54)
The Annals Of Pharmacotherapy
(52)
Plos One
(49)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(7)
... seit 90 Tagen
(46)

Menü

Weitere Dienste

Einstellungen

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Two Phase 3 Trials of Baricitinib for Alopecia Areata

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

JAK inhibitors in dermatology: The promise of a new drug class

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Suchergebnisse filtern